Tirzepatide

Tirzepatide is a glucose-lowering and weight-lowering medication in the incretin mimetic class, set apart by its action on two hormone receptors rather than one ^[2]. Chemically it is a synthetic 39-amino-acid peptide modeled on gastric inhibitory polypeptide, also called glucose-dependent insulinotropic polypeptide or GIP, and it carries a C20 fatty diacid chain that binds albumin and extends its circulating half-life to roughly five days, which allows once-weekly subcutaneous dosing ^[2][3]. The molecule was engineered by Eli Lilly under the development code LY3298176 to test whether adding GIP activity to established GLP-1 receptor agonism would improve metabolic outcomes ^[2].

In the SURPASS program for type 2 diabetes, tirzepatide reduced glycated hemoglobin and body weight more than the selective GLP-1 receptor agonists dulaglutide and semaglutide ^[1][5]. The later SURMOUNT obesity trials reported mean weight reductions of roughly fifteen to twenty-one percent over seventy-two weeks in adults without diabetes, well beyond placebo ^[4]. The United States Food and Drug Administration approved it for type 2 diabetes in 2022 under the name Mounjaro, and for chronic weight management in 2023 under the name Zepbound; an additional indication for moderate-to-severe obstructive sleep apnea in adults with obesity followed in late 2024. Regulators in the European Union, the United Kingdom, Canada, and Australia have granted comparable approvals, and the medication is prescription-only in these markets.

Tirzepatide is supplied as a subcutaneous injection given once weekly, available in prefilled pens and vials. The most frequently reported adverse effects are gastrointestinal, including nausea, diarrhea, reduced appetite, vomiting, and constipation, and they tend to emerge during dose escalation ^[1][4]. Product labeling carries warnings related to a personal or family history of medullary thyroid carcinoma and to multiple endocrine neoplasia type 2. Ongoing research has examined cardiovascular outcomes, prevention of progression from prediabetes to overt diabetes, and metabolic dysfunction-associated steatotic liver disease ^[5].

The most common effects are dose-dependent GI ones (nausea, vomiting, diarrhea, constipation), and hypoglycemia can occur when it is combined with insulin or sulfonylureas. It carries a boxed warning for thyroid C-cell tumors (a rodent finding) and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2; pancreatitis and gallbladder events have also been reported. Prescription, injectable.

Tirzepatide slows gastric emptying, which can alter the rate and extent of absorption of concomitantly administered oral drugs; the label specifically warns that it may reduce the efficacy of oral hormonal contraceptives, and advises switching to a non-oral method or adding a barrier method for four weeks after starting and after each dose increase. When combined with insulin or insulin secretagogues such as sulfonylureas, the risk of hypoglycemia rises, so the label recommends lowering the dose of those agents. Its gastric-emptying effect is greatest at initiation and diminishes over time, making narrow-therapeutic-index oral drugs the main practical concern. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Tirzepatide was developed by Eli Lilly under the code LY3298176 as a first-in-class agonist that activates the receptors for two gut incretin hormones, GIP and GLP-1, at the same time. It is a synthetic 39-amino-acid peptide engineered for once-weekly dosing and represents a deliberate step beyond single-hormone incretin drugs. The US Food and Drug Administration first approved it in 2022 as Mounjaro for type 2 diabetes, followed in 2023 by Zepbound for chronic weight management, and it was later authorized for obstructive sleep apnea. Its development reflected a broader shift toward multi-receptor agonists in cardiometabolic medicine.

Tirzepatide has earned a strong reputation for the depth of weight loss and glucose control it can produce, with its SURMOUNT and SURPASS trial programs frequently cited as setting a high benchmark for the field. Commentators often point to its dual incretin mechanism as a possible reason for effects that appear to exceed those of single-hormone agonists, alongside improvements in blood pressure, lipids, and markers of insulin sensitivity. Its once-weekly schedule and expanding list of approved uses add to its appeal. Balanced discussion acknowledges that gastrointestinal side effects such as nausea and diarrhea are common, that weight tends to be regained if treatment stops, and that long-term outcome data are still accumulating. Overall it is regarded as one of the most effective agents in its class while remaining under active study.